Creabilis adds three executives to management team
Reflects growing confidence in pipeline and science that underpins it
Alex Leech joins as vice president, head of finance and operations, James Sandy as senior vice president, head of development, and Peter Spargo as senior vice president for chemistry manufacturing and controls (CMC).
Leech was most recently head of operations at Solace Pharmaceuticals. Prior to this, he worked for the Pfizer r&d organisation where he was head of European project management. He has also held a number of operational and engineering management roles at Ford. Sandy was most recently at Pfizer as development team leader of Pfizer’s GI portfolio. Prior to working at Pfizer, he was head of biometrics at Astra UK.
Spargo was most recently at Novexel as senior vice president of CMC. Prior to this he was head of chemical process r&d for Pfizer in Europe.
Eliot Forster, ceo of Creabilis, said: ‘This expansion of our senior management team reflects Creabilis’ growing maturity and the confidence we have in our pipeline, our science and the culture that underpins it.’
You may also like
Research & Development
CAR T-cell therapy shows promise for restoring gut health and intestinal regeneration
Researchers at Cold Spring Harbor Laboratory have demonstrated that anti-uPAR CAR T-cell therapy can clear senescent cells and restore intestinal regeneration, offering a potential new approach to treating age- and radiation-related gut damage
Research & Development
New Osaka-developed reverse genetics system accelerates norovirus vaccine and drug research
Osaka University scientists have created the first simple, efficient system to generate infectious human noroviruses, paving the way for faster antiviral screening and vaccine development
Research & Development
Chemify secures $1.6m Gates Foundation grant to accelerate digital chemistry for tuberculosis drug discovery
The follow-on funding supports Chemify and Lgenia in designing and synthesising new small-molecule candidates for high-priority TB targets using Chemify’s AI-driven digital chemistry platform
Research & Development
PLL Therapeutics opens New Zealand subsidiary to accelerate ALS clinical research in Asia-Pacific
The new entity will support Phase II ALS patient recruitment in New Zealand (where incidence rates exceed the global average) and expand PLL Therapeutics’ footprint in the Asia-Pacific neurodegenerative disease research landscape
Research & Development
Poolbeg Pharma trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme
Poolbeg will act as the lead business partner, alongside Johnson & Johnson and other partners, on the University of Manchester and The Christie NHS Foundation Trust research programme titled RISE (Reducing Immune Stress from Excess cytokine release in advanced therapies)